An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies.
DNA vaccine therapy
Gene therapy
cytokine therapy
immune cell therapy
tumor suppressor gene therapy
Journal
Cancer informatics
ISSN: 1176-9351
Titre abrégé: Cancer Inform
Pays: United States
ID NLM: 101258149
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
07
2022
accepted:
24
12
2022
entrez:
10
2
2023
pubmed:
11
2
2023
medline:
11
2
2023
Statut:
epublish
Résumé
Genomic instability is considered a fundamental factor involved in any neoplastic disease. Consequently, the genetically unstable cells contribute to intratumoral genetic heterogeneity and phenotypic diversity of cancer. These genetic alterations can be detected by several diagnostic techniques of molecular biology and the detection of alteration in genomic integrity may serve as reliable genetic molecular markers for the early detection of cancer or cancer-related abnormal changes in the body cells. These genetic molecular markers can detect cancer earlier than any other method of cancer diagnosis, once a tumor is diagnosed, then replacement or therapeutic manipulation of these cancer-related abnormal genetic changes can be possible, which leads toward effective and target-specific cancer treatment and in many cases, personalized treatment of cancer could be performed without the adverse effects of chemotherapy and radiotherapy. In this review, we describe how these genetic molecular markers can be detected and the possible ways for the application of this gene diagnosis for gene therapy that can attack cancerous cells, directly or indirectly, which lead to overall improved management and quality of life for a cancer patient.
Identifiants
pubmed: 36762284
doi: 10.1177/11769351221150772
pii: 10.1177_11769351221150772
pmc: PMC9903029
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
11769351221150772Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Nat Rev Clin Oncol. 2021 Feb;18(2):85-100
pubmed: 32934330
Int J Mol Sci. 2019 Nov 12;20(22):
pubmed: 31718077
Immune Netw. 2020 Mar 09;20(2):e14
pubmed: 32395366
Diseases. 2020 Sep 07;8(3):
pubmed: 32906694
Ther Innov Regul Sci. 2018 Nov;52(6):701-707
pubmed: 29714581
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Front Bioeng Biotechnol. 2018 Mar 28;6:34
pubmed: 29644216
Front Genet. 2021 Nov 01;12:770134
pubmed: 34790230
Br J Cancer. 2019 Jan;120(1):6-15
pubmed: 30413827
Cells. 2021 Feb 06;10(2):
pubmed: 33562057
Arch Pharm Res. 2019 Jul;42(7):543-548
pubmed: 30859410
Bioengineered. 2022 May;13(5):12847-12862
pubmed: 35611845
Pharmacol Ther. 2020 Mar;207:107458
pubmed: 31863816
Curr Issues Mol Biol. 2017;22:129-138
pubmed: 27831541
Trends Immunol. 2020 Aug;41(8):676-691
pubmed: 32622854
Trends Genet. 2016 Jun;32(6):360-371
pubmed: 27129983
Front Immunol. 2020 May 21;11:924
pubmed: 32508825
Semin Cell Dev Biol. 2018 Dec;84:11-21
pubmed: 29246859
Methods Mol Biol. 2018;1708:447-472
pubmed: 29224158
Biomolecules. 2022 Jul 04;12(7):
pubmed: 35883495
Pathol Oncol Res. 2017 Jan;23(1):63-71
pubmed: 27377733
Gene Ther. 2011 Jul;18(7):674-81
pubmed: 21368897
Eur J Med Res. 2013 Oct 04;18:37
pubmed: 24093889
J Clin Med. 2017 Jan 04;6(1):
pubmed: 28054963
Acta Cytol. 2019;63(6):449-455
pubmed: 31091522
Nat Rev Mater. 2021;6(12):1078-1094
pubmed: 34394960
Comput Intell Neurosci. 2022 Sep 19;2022:9591781
pubmed: 36172325
Science. 2020 Jan 10;367(6474):131
pubmed: 31919200
Trends Biochem Sci. 2015 Nov;40(11):701-714
pubmed: 26439531
Cell Cycle. 2019 Dec;18(24):3442-3455
pubmed: 31726940
Cancer. 2019 Dec 1;125(23):4139-4147
pubmed: 31433498
Medicine (Baltimore). 2017 Feb;96(7):e6097
pubmed: 28207521
Front Immunol. 2017 Apr 26;8:458
pubmed: 28491060
J Immunol Methods. 2020 Feb;477:112690
pubmed: 31678265
Orv Hetil. 2019 Jul;160(30):1167-1177
pubmed: 31327245
Immune Netw. 2018 Apr 03;18(2):e17
pubmed: 29732235
Nat Med. 2022 Apr;28(4):678-689
pubmed: 35440724
J Oncol. 2021 Apr 12;2021:6627241
pubmed: 33936202
Hepatol Int. 2019 Mar;13(2):125-137
pubmed: 30600478
Cell Res. 2017 Jan;27(1):74-95
pubmed: 28025976
Drug Resist Updat. 2020 May;50:100682
pubmed: 32087558
Mol Biol Rep. 2022 Mar;49(3):2097-2105
pubmed: 34854010
Oral Maxillofac Surg Clin North Am. 2019 Feb;31(1):117-124
pubmed: 30454787
J Oral Pathol Med. 2022 May;51(5):429-435
pubmed: 35416334
Med Biol Eng Comput. 2021 Nov;59(11-12):2353-2371
pubmed: 34609687
Cancers (Basel). 2021 Aug 03;13(15):
pubmed: 34359820
Cold Spring Harb Protoc. 2017 Mar 1;2017(3):
pubmed: 27574194
Int J Mol Sci. 2018 Feb 01;19(2):
pubmed: 29389901
Discov Med. 2019 Jan;27(146):45-55
pubmed: 30721651
Redox Biol. 2019 Jul;25:101174
pubmed: 30917934
Semin Immunol. 2021 Feb;52:101481
pubmed: 34023170
Cancer Drug Resist. 2022 Jun 21;5(3):541-559
pubmed: 36176757
Nature. 2017 Oct 19;550(7676):345-353
pubmed: 29019985
Cell. 2020 Mar 19;180(6):1280-1280.e1
pubmed: 32200803
Pharmaceutics. 2022 Sep 03;14(9):
pubmed: 36145609
Med Princ Pract. 2021;30(1):1-16
pubmed: 32841942
Int J Mol Sci. 2022 Sep 06;23(18):
pubmed: 36142151
N Engl J Med. 2018 Apr 05;378(14):1323-1334
pubmed: 29617578
Nat Rev Cancer. 2022 Oct;22(10):557-575
pubmed: 35879429
Curr Opin Oncol. 2013 Nov;25(6):659-64
pubmed: 24100345
Immunol Rev. 2019 Jul;290(1):85-99
pubmed: 31355489
Appl Biosaf. 2020 Dec 1;25(4):184-193
pubmed: 36032394
Crit Rev Oncol Hematol. 2020 Nov;155:103109
pubmed: 33049662
Expert Rev Mol Diagn. 2018 Jan;18(1):85-112
pubmed: 29134827
Clin Chem. 2013 Jan;59(1):60-7
pubmed: 23160065
Essays Biochem. 2019 Dec 20;63(6):797-811
pubmed: 31845735
J Dermatol. 2022 Jan;49(1):161-164
pubmed: 34601768
Life Sci. 2020 Aug 1;254:117580
pubmed: 32205087
Bioinformatics. 2020 Mar 1;36(6):1712-1717
pubmed: 32176769
Recent Results Cancer Res. 2020;215:263-273
pubmed: 31605234
Front Oncol. 2021 Oct 11;11:754891
pubmed: 34707997
Cancer Lett. 2020 Apr 28;476:1-12
pubmed: 32044356
JAMA. 2017 Sep 5;318(9):825-835
pubmed: 28873162
BMC Med. 2012 Aug 09;10:87
pubmed: 22876833
Semin Immunol. 2017 Jun;31:37-54
pubmed: 28838796
Sci Transl Med. 2020 Jan 1;12(524):
pubmed: 31894106
Cells. 2020 Dec 31;10(1):
pubmed: 33396222
Methods Mol Biol. 2019;1986:17-33
pubmed: 31115883
Cancer Cell. 2020 Oct 12;38(4):454-472
pubmed: 32822573
Cancer Lett. 2020 Jan 1;468:59-71
pubmed: 31610267
Front Immunol. 2018 Dec 20;9:2987
pubmed: 30619342
Cell Mol Biol (Noisy-le-grand). 2020 Jun 05;66(3):1-7
pubmed: 32538773
Drug Des Devel Ther. 2021 May 27;15:2269-2287
pubmed: 34079226
Expert Rev Vaccines. 2016;15(3):313-29
pubmed: 26707950
Biochim Biophys Acta. 2010 Dec;1806(2):251-7
pubmed: 20708654
Am J Clin Pathol. 2015 Jan;143(1):18-24
pubmed: 25511138
PLoS One. 2020 Jul 7;15(7):e0235611
pubmed: 32634139
Front Public Health. 2017 Apr 11;5:77
pubmed: 28443278
Sci Rep. 2017 Nov 30;7(1):16607
pubmed: 29192280
Clin Chim Acta. 2013 Sep 23;424:53-65
pubmed: 23669186
JCO Precis Oncol. 2022 Feb;6:e2100337
pubmed: 35188804
Theranostics. 2020 Mar 26;10(11):4737-4748
pubmed: 32308746
Nat Protoc. 2017 Feb;12(2):213-218
pubmed: 28055035
Front Immunol. 2020 Jun 23;11:1314
pubmed: 32655576
Bioessays. 2015 Dec;37(12):1277-86
pubmed: 26445307
Anticancer Res. 2020 Nov;40(11):6009-6015
pubmed: 33109539
Int Rev Cell Mol Biol. 2019;348:123-178
pubmed: 31810552
Clin Chem Lab Med. 2019 Feb 25;57(3):312-316
pubmed: 30465714
Front Immunol. 2021 Feb 17;12:646523
pubmed: 33679809
Pharmacol Ther. 2013 Sep;139(3):392-404
pubmed: 23711794
Front Immunol. 2018 Jun 26;9:1450
pubmed: 29997620
J Hematol Oncol. 2019 May 29;12(1):52
pubmed: 31142330
Int J Mol Sci. 2020 Dec 03;21(23):
pubmed: 33287451
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2568-2574
pubmed: 32277003
Clin Chem. 2017 May;63(5):963-972
pubmed: 28270433
Cancer. 2015 May 1;121(9):1357-68
pubmed: 25557041
Nat Commun. 2020 Oct 27;11(1):5376
pubmed: 33110059
Am J Dermatopathol. 2013 Jun;35(4):432-7
pubmed: 23689692
Mol Ther. 2017 Aug 2;25(8):1769-1781
pubmed: 28668320
Nat Rev Immunol. 2017 Jan;17(1):30-48
pubmed: 27890914
Cancer Inform. 2022 Feb 7;21:11769351221076062
pubmed: 35153470
Methods Mol Biol. 2019;1894:181-227
pubmed: 30547463
Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S115-21
pubmed: 14508088
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):251-258
pubmed: 28374743
Ir J Med Sci. 2021 Feb;190(1):41-57
pubmed: 32607912
EBioMedicine. 2020 Sep;59:102975
pubmed: 32853984
Curr Opin Hematol. 2020 Mar;27(2):49-57
pubmed: 31972687
Int J Mol Sci. 2022 Apr 18;23(8):
pubmed: 35457259
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Future Oncol. 2018 Apr;14(10):907-917
pubmed: 29260582
Sci Adv. 2020 Nov 11;6(46):
pubmed: 33177077
Medicine (Baltimore). 2020 Apr;99(16):e19828
pubmed: 32312003
Open Biol. 2018 Jun;8(6):
pubmed: 29875199
Drugs R D. 2007;8(3):176-87
pubmed: 17472413
Appl Biosaf. 2019 Sep 1;24(3):147-152
pubmed: 36032336
Oncol Lett. 2021 Sep;22(3):655
pubmed: 34386077
Rep Biochem Mol Biol. 2017 Oct;6(1):95-101
pubmed: 29090235
Adv Exp Med Biol. 2020;1255:133-142
pubmed: 32949396
Nat Commun. 2020 Jul 21;11(1):3475
pubmed: 32694610
Nat Rev Cancer. 2016 Jan;16(1):7-19
pubmed: 26694935
Mol Ther Nucleic Acids. 2018 Jun 1;11:508-514
pubmed: 29858085
Expert Opin Biol Ther. 2013 Nov;13(11):1569-83
pubmed: 24107178
Pharmacol Rep. 2020 Oct;72(5):1125-1151
pubmed: 32700248
J Immunol. 2018 Jan 15;200(2):443-449
pubmed: 29311386
Mol Cancer. 2020 Aug 6;19(1):120
pubmed: 32762681
Cancers (Basel). 2021 Oct 15;13(20):
pubmed: 34680322
BMC Med Genomics. 2019 Jan 15;12(1):10
pubmed: 30646919
Nat Commun. 2021 Aug 6;12(1):4755
pubmed: 34362890
Front Immunol. 2019 Oct 29;10:2393
pubmed: 31736936
Pathogens. 2021 Nov 22;10(11):
pubmed: 34832679
Genet Test Mol Biomarkers. 2019 Apr;23(4):277-283
pubmed: 30986103
Reprod Biol Endocrinol. 2021 Dec 3;19(1):178
pubmed: 34861867
Drug Deliv. 2017 Nov;24(1):289-299
pubmed: 28165834
J Interferon Cytokine Res. 2019 Jan;39(1):6-21
pubmed: 29889594
Gene Ther. 2018 Apr;25(2):115-128
pubmed: 29563582
Int J Mol Sci. 2017 Mar 17;18(3):
pubmed: 28304339